CRT in the presence of marked intraventricular mechanical dyssynchrony, regardless of narrow QRS duration.
Methods Patients
The NARROW-CRT study was a prospective, randomized, singleblind, multicenter evaluation of CRT in patients who were candidates for cardioverter-defibrillator implantation, with New York Heart Association (NYHA) class II and III HF, ischemic cardiomyopathy, an ejection fraction of ≤35%, a QRS interval of ≤120 ms, and evidence of mechanical dyssynchrony as measured on echocardiography. Patients were excluded from the study if they had a conventional indication for cardiac pacing, persistent atrial fibrillation, or a life expectancy <1 year.
Study Design
Patients meeting eligibility requirements underwent baseline evaluation, which included demographics and medical history, clinical examination, 12-lead ECG, estimation of NYHA functional class, and echocardiographic evaluation.
In the presence of intraventricular mechanical dyssynchrony on echocardiography, as defined below, patients were randomly assigned to CRT defibrillator (CRT-D) or dual-chamber implantable cardioverter-defibrillator (D-ICD) groups in a 1:1 ratio according to center, by sealed-envelope technique. Block randomization was by a computer-generated random number list prepared by an investigator with no clinical involvement in the trial.
In the absence of mechanical dyssynchrony, patients were included in a prospective registry and received a single-or dual-chamber defibrillator at the discretion of the implanting physician.
The CRT-D group underwent implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator, and LV leads. The target location for the LV lead tip was the lateral or posterolateral segment. The D-ICD group received a dual-chamber defibrillator with a right atrial and right ventricular lead, by means of standard techniques.
In the D-ICD group, the defibrillator was programmed to minimize right ventricular pacing. In both groups, the ventricular fibrillation detection cutoff rate was required to be 200 beats/min. Enrolled patients returned for regular clinic visits at 6 and 12 months, and every 6 months thereafter until the last patient reached the 1-year evaluation. In addition to clinical evaluation, devicerecorded arrhythmic episodes were retrieved from the defibrillator memory at each follow-up visit. In addition, echocardiography was performed at the 1-year follow-up visit in patients with CRT-D. The Institutional Review Boards approved the study, and all patients gave written informed consent.
End Points
The primary end point of the study was the HF clinical composite score. 15 In detail, at the 12-month follow-up evaluation, patients were classified according to a score, which assigns subjects to 1 of 3 response groups-improved, worsened, or unchanged. Patients were judged to have worsened if they died or were hospitalized because of worsening HF (at any time during the 12 months), or displayed worsening in NYHA functional class or patient global assessment at their 12-month visit. Patients were judged to have improved if they had not worsened, and had displayed improvement in NYHA functional class and patient global assessment at 12 months. Patients who had neither worsened nor improved were classified as unchanged. Only hospitalizations requiring ≥1 overnight stay, and which were adjudicated as related to HF by a blinded End Point Advisory Committee, contributed to the end point.
Implanting physicians and study site personnel involved in device management were unblinded to randomization assignment. Conversely, patients, treating physicians, and site personnel taking the functional measurements of NYHA classification did not know to which arm the subject had been randomized.
The secondary end point was the cumulative survival from HF hospitalization and HF death. An additional secondary end point was the composite of HF hospitalization, HF death, and spontaneous ventricular fibrillation. 16 Spontaneous sustained arrhythmic episodes detected by the device were validated by 2 blinded electrophysiologists. If a consensus could not be reached, a third electrophysiologist was called on to adjudicate. A sustained arrhythmia was defined a priori as one treated by the device. All device-detected arrhythmias correctly classified as ventricular fibrillations and appropriately terminated by shock therapy were counted as end points.
The effects of CRT on echocardiographic parameters were evaluated by comparing the baseline values with those recorded at the 12-month follow-up examination of surviving patients. Moreover, the cumulative survival from death or HF hospitalization and from the combined end point of HF death or hospitalization, and shockterminated spontaneous ventricular fibrillation in the study arms were also compared with those of the parallel group with no baseline mechanical dyssynchrony.
Echocardiographic Analysis
Echocardiographic analysis was performed at the baseline evaluation in all screened patients and at follow-up visits in patients with CRT-D. The level of intraventricular mechanical dyssynchrony was determined by means of tissue Doppler imaging.
As previously described, 6 color Doppler imaging was performed by first acquiring standard apical views of 2 chambers, 3 chambers, and 4 chambers at high frame rates. The sample volume was placed offline in the basal portions of the septal and lateral walls, and velocity curves were generated. Peak systolic velocities and time-to-peak systolic velocities were recorded. A difference between the septal and lateral delays of ≥60 ms was defined as a significant intraventricular mechanical delay. 6 Echocardiographic recordings were reviewed in a core laboratory to confirm eligibility of enrolled patients. If the presence of intraventricular mechanical dyssynchrony was not confirmed by the operator, a second sonographer at the core laboratory was called on to adjudicate. If the absence of dyssynchrony criteria was verified, the patient exited the study.
The following parameters were also recorded: LV end-diastolic and end-systolic volumes and diameters, and ejection fraction assessed by means of Simpson equation.
Statistical Analysis
All end points were analyzed according to the intention-to-treat principle, and analyses were stratified by center. For the prespecified analysis of the primary end point, the percentage of patients in the 2 study groups who had improved was compared by means of the Mantel-Haenszel χ 2 test to assess the efficacy of CRT.
The sample size (60 patients per treatment group) was estimated on the basis of the assumption that the study would have 80% power to detect a difference of 25% in improved HF clinical composite responses, as reported in previous CRT trials. 14, 17 The proportion of patients in the CRT-D group who would improve was assumed to be 38%, 14 with an attrition rate of 10% from randomization to the end of study.
Kaplan-Meier analysis was used to analyze cumulative survival from HF hospitalization and HF death and cumulative survival from the combined end point of HF hospitalization, HF death, and spontaneous ventricular fibrillation, and the log-rank test was used to assess significance. Additionally, Cox model with robust standard errors was used to analyze end points to account for intrasite correlation.
Descriptive statistics are reported as means±SD for normally distributed continuous variables or medians with 25th to 75th percentiles in the case of skewed distribution. Differences between mean data were compared by means of a t test for gaussian variables. The Mann-Whitney test and the Wilcoxon nonparametric test were used to compare nongaussian variables for independent and paired samples, respectively. Differences in proportions were compared by applying χ 2 analysis or Fisher exact test, as appropriate.
A P value <0.05 was considered significant for all tests. All statistical analyses were performed by using STATISTICA software, version 7.1 (StatSoft, Inc., Tulsa, OK).
Results

Study Timelines and Population
From January 2008 through May 2010, a total of 1290 patients referred to the 6 centers for cardioverter-defibrillator implantation for primary prevention of sudden cardiac death were initially screened. Of these, 233 patients met eligibility requirements and underwent the baseline evaluation. On echocardiographic analysis, mechanical dyssynchrony was detected in 120 patients, who were randomly assigned to the CRT-D or D-ICD arms. In 3 additional patients, mechanical dyssynchrony was diagnosed at the local site but not confirmed after core laboratory review. Thus, these patients exited the study before randomization.
Demographic data, clinical parameters, and pharmacological treatment were similar between the study arms at the time of enrollment ( Table 1 ). The majority of LV leads (42 out of 60; 70%) were deployed in a lateral or posterolateral cardiac vein. Two patients in the CRT-D arm did not undergo successful implantation of the LV lead; these received a dual-chamber defibrillator, but remained in the CRT-D arm in accordance with the intention-to-treat design of the analysis. During the course of the study, 9 patients were lost to follow-up or exited the study (4 in the CRT-D arm and 5 in the D-ICD arm), while there were no crossovers ( Figure 1 ). The median length of follow-up was comparable between groups: 16 months (12-24) versus 15 months (9-24; P=0.325).
The median percentage of biventricular pacing in the CRT-D arm was 97% (93-100) at 6 months and 99% (96-100) at 1 year. In the D-ICD arm, the median percentage of right ventricular pacing was 1% (0-8) at 6 months and 1% (0-7) at 1 year.
Effects on Primary and Secondary End Points
Of the 56 patients assigned to CRT-D, 23 (41%) patients displayed an improvement in their HF clinical composite response at 1 year compared with 9 (16%) of the 55 patients randomized to D-ICD (P=0.004; Figure 2 ). Details of the components considered in the calculation of the end points are listed in Table 2 .
By the end of the study, 4 patients in the CRT-D arm had died (2 of pump failure and 2 of noncardiac causes) and 5 D-ICD patients had died of pump failure. One patient in the CRT-D arm and 1 patient in the D-ICD arm died of pump failure during the first 12 months. All the remaining patients completed their 12-month follow-up visit. The Kaplan-Meier analysis showed a nonsignificant higher survival from HF hospitalization and HF death (P=0.077), and a significantly higher survival from the combined end point of HF hospitalization, HF death, and spontaneous ventricular fibrillation (P=0.028) in the CRT-D arm (Figure 3) .
During follow-up, incisional infections at the pocket site were reported in 2 patients in the CRT-D arm and in 1 patient in the D-ICD arm; phrenic-nerve stimulation was reported in 3 CRT-D patients, and was corrected by means of device reprogramming. Moreover, 1 CRT-D patient and 1 D-ICD patient had pocket hematoma.
A significant increase in LV ejection fraction was observed in the CRT-D arm after 12 months (Table 3) , together with a reduction in systolic dimensions (LV end-systolic volume and LV end-systolic diameter), whereas diastolic dimensions (LV end-diastolic volume and LV end-diastolic diameter) did not show significant changes. CRT significantly reduced the intraventricular mechanical delay, and 21% of patients with CRT-D presented at the 1-year visit with a mechanical delay of ≤60 ms.
The baseline characteristics of the patients included in the registry of subjects with no mechanical dyssynchrony on baseline evaluation and treated with non-CRT devices ( Table 1) were comparable with those of the patients in analysis who underwent randomization, except for slightly shorter QRS duration, smaller LVEDD, a significantly higher proportion of patients in NYHA class II. Obviously, also the mean intraventricular mechanical delay was markedly shorter. During the course of the study, 15 patients in the registry were lost to follow-up, 7 patients died (6 of pump failure and 1 of noncardiac causes), and 11 patients were hospitalized because of worsening HF. Moreover, 7 patients had a shock-terminated spontaneous ventricular fibrillation.
Kaplan-Meier estimates of survival from HF hospitalization and death and from the combined end point of HF hospitalization, HF death, and spontaneous ventricular fibrillation were made for patients with no baseline mechanical dyssynchrony; these were then compared with the estimates made in the CRT-D and D-ICD study arms (Figure 4) . The CRT-D group displayed an event rate comparable with that of the group with no evidence of mechanical dyssynchrony, whereas the D-ICD group presented a significantly worse outcome.
Discussion
Primary End Point Analysis
In the NARROW-CRT trial, CRT improved clinical status, as measured by the clinical composite score, in patients with HF with ischemic cardiomyopathy and marked intraventricular mechanical dyssynchrony, regardless of narrow QRS duration.
Among patients with current indications, that is, QRS ≥120 ms, those with significant QRS prolongation seem to derive the most benefit from CRT and to have a better prognosis, according to the post hoc analyses of large CRT trials. [3] [4] [5] Moreover, left bundle-branch block QRS morphology was found to be a predictor of functional status improvement, 16 and reduction in HF progression and in the risk of ventricular tachyarrhythmias. 18 This seems to contradict the well-known association between prolonged QRS duration and poor prognosis. 19 The lesser efficacy of CRT in patients with HF with normal QRS duration may reflect the lower prevalence of mechanical dyssynchrony in such patients. [7] [8] [9] Indeed, although some studies on the effect of CRT in patients with narrow QRS have enrolled unselected patients, 10 the majority have adopted additional selection methods to detect amenable mechanical dyssynchrony and to identify potential candidates for CRT. [11] [12] [13] [14] Although the majority of single-center experiences have shown a positive response to CRT in patients with narrow QRS, 10-13 1 randomized study that enrolled patients with QRS duration of <130 ms (the RethinQ [Resynchronization Therapy in Normal QRS] trial) did not show any improvement in peak oxygen consumption on CRT. 14 Peak oxygen consumption, however, is poorly associated with symptoms 20 and, thus, is not an adequate surrogate measure of symptomatic benefit in patients with HF. Indeed, in the Multicenter InSync ICD Randomized Clinical Evaluation II (MIRACLE ICD II) trial, 21 CRT failed to improve peak oxygen uptake, despite a significant improvement in NYHA class. Moreover, the RethinQ trial did demonstrate both an improvement in NYHA class and fewer HF events in the CRT group.
As the primary end point of our study, we adopted the clinical composite score, because this combines the occurrence of major events, such as HF hospitalization and mortality, with NYHA functional class. 15 This score has proved to be sensitive in detecting the presence or absence of a true CRT effect in both moderate and mild HF 17, 21, 22 and, thus, in the stages of disease considered in the present study. Unlike the RethinQ trial, we also enrolled patients in NYHA class II, in line with current CRT recommendations. 2 However, although CRT indication was extended to mildly symptomatic patients in the recent update of the European guidelines, the QRS width cutoff was increased from 120 to 150 ms in these patients, because randomized trials had seemed to demonstrate that the favorable effect of CRT was limited to patients with longer QRS duration. 5
Secondary End Point Analysis
Our trial showed that CRT could improve survival from clinical events, such as death or hospitalization for worsening of HF, although the increase was not significant in the present analysis. Nonetheless, survival from the combined end point of HF hospitalization, HF death, and spontaneous ventricular fibrillation, adopted as end points in previous large CRT trials, 16, 18 was significantly improved. It had previously been shown that CRT could reduce sudden death, 23 but this ability was seen to be delayed and seemed to depend on improvements in cardiac function. Indeed, CRT is associated with a reversal of structural remodeling and has been shown to lessen the risk of malignant arrhythmia. 24 Although it has been demonstrated that defibrillator shocks occur more frequently than sudden cardiac deaths and, thus, should not be regarded as a surrogate for fatal events, the reduced risk of arrhythmias on CRT will translate into fewer therapeutic shocks in a population of defibrillator recipients, which will potentially improve quality of life and further enhance the clinical outcome.
Identification of Mechanical Dyssynchrony and Patient Selection
The method that we selected to identify mechanical dyssynchrony is one of the most frequently adopted in the literature 6 and is the same as was used in the RethinQ trial. In the PROSPECT (Predictors of Response to Cardiac Re-Synchronization Therapy) trial, 25 the time difference between lateral and septal peak systolic wall velocities was the only tissue Doppler imaging-based test, which demonstrated a significantly higher level of CRT response among patients meeting the cutoff criterion.
In our series, we only included patients with HF of ischemic origin. Among patients with narrow QRS, conduction delays and consequent inhomogeneities in ventricular activation are more frequently caused by ischemic endocardial damage rather than by discrete bundle-branch disease. This was apparent both in the post hoc MADIT-CRT analysis, in which the group with narrow QRS was mainly composed of ischemic patients, 18 and in the recent study by Foley et al, 26 who tested the efficacy of CRT in patients with normal QRS complex (<120 ms) who were not selected on the basis of mechanical dyssynchrony. In line with our findings, these authors were able to demonstrate an improvement in symptoms, exercise capacity, and quality of life on CRT. In their randomized study, they used late gadolinium-enhancement cardiovascular magnetic resonance scans to deploy the LV lead over nonscarred myocardium. However, although the avoidance of pacing myocardial scars could have produced a more favorable response to CRT, no other studies have used such a technique, and further studies are needed to confirm this hypothesis.
About half of our patients with a QRS interval of ≤120 ms presented evidence of mechanical dyssynchrony on baseline echocardiography. This finding closely matches that reported by Foley et al, 26 despite the different technique adopted for intraventricular dyssynchrony assessment. Confirming their results, in the CRT-D group, we observed a significant reduction in the septal-to-lateral wall motion delay, which in 21% of patients turned out to have normalized during follow-up. Moreover, the rate of clinical events in the CRT-D group was comparable with that recorded in patients with no mechanical dyssynchrony, whereas patients with dyssynchrony and D-ICD showed a worse outcome. This seems to suggest that, in patients with a normal QRS duration, cardiac dyssynchrony is associated with a worse prognosis, but that it may be effectively corrected by means of CRT, with consequent improvement in the clinical outcome.
Limitations
The sample size was small and, although the statistical power was sufficient to address the primary end point, the study was not powered to detect differences in its secondary end points. Moreover, although patients and the physicians measuring functional status were blinded to randomization assignment, our primary end point was relatively subjective, and some bias could have entered into the decision to hospitalize the patient. The use of CRT-D devices in the control arm, with inhibited ventricular pacing, would have improved the study blinding, but increased procedural and long-term risks.
Measuring additional outcome variables (eg, quality of life, 6-minute walking distance, peak oxygen consumption) would have enhanced the validity of the present findings. Furthermore, the lack of follow-up echocardiographic data in the D-ICD arm did not permit us to exclude the occurrence of similar changes among patients with dual-chamber defibrillators.
Conclusions
On the basis of the results of the NARROW-CRT study, which compared CRT defibrillators with dual-chamber defibrillators, it can be hypothesized that CRT improves clinical status in some patients with mild-to-moderate HF of ischemic origin and mechanical dyssynchrony, regardless of narrow QRS duration. However, pending the final results of the ongoing EchoCRT (Echocardiography Guided Cardiac Resynchronization Therapy) trial, 27 this hypothesis remains to be verified. 
